SwePub
Sök i LIBRIS databas

  Extended search

id:"swepub:oai:DiVA.org:lnu-56076"
 

Search: id:"swepub:oai:DiVA.org:lnu-56076" > Preclinical profile...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Preclinical profile of ITI-214, an inhibitor of phosphodiesterase 1, for enhancement of memory performance in rats

Snyder, Gretchen L. (author)
Intra-Cellular Therapies Inc, USA
Prickaerts, Jos (author)
Maastricht University, The Netherlands
Wadenberg, Marie-Louise (author)
Linnéuniversitetet,Institutionen för kemi och biomedicin (KOB)
show more...
Zhang, Lei (author)
Intra-Cellular Therapies Inc, USA
Zheng, Hailin (author)
Intra-Cellular Therapies Inc, USA
Yao, Wei (author)
Intra-Cellular Therapies Inc, USA
Akkerman, Sven (author)
Maastricht University, The Netherlands
Zhu, Hongwen (author)
Tianjin Hospital, China
Hendrick, Joseph P. (author)
Intra-Cellular Therapies Inc, USA
Vanover, Kimberly E. (author)
Intra-Cellular Therapies Inc, USA
Davis, Robert (author)
Intra-Cellular Therapies Inc, USA
Li, Peng (author)
Intra-Cellular Therapies Inc, USA
Mates, Sharon (author)
Intra-Cellular Therapies Inc, USA
Wennogle, Lawrence P. (author)
Intra-Cellular Therapies Inc, USA
show less...
 (creator_code:org_t)
2016-06-24
2016
English.
In: Psychopharmacology. - : Springer Science and Business Media LLC. - 0033-3158 .- 1432-2072. ; 233:17, s. 3113-3124
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Rationale: Therapeutic agents for memory enhancement in psychiatric disorders, such as schizophrenia, are urgently needed.Objective: The aim of this study is to characterize the preclinical profile of ITI-214, a potent inhibitor of phosphodiesterase 1 (PDE1).Methods: ITI-214 was assayed for inhibition of PDE1 versus other PDE enzyme families using recombinant human PDE enzymes and for off-target binding to 70 substrates (General SEP II diversity panel; Caliper Life Sciences). Effects of ITI-214 (0.1–10 mg/kg, po) on memory performance were assayed in rats using the novel object recognition (NOR) paradigm, with drug given at specified time points prior to or following exposure to objects in an open field. ITI-214 was evaluated for potential drug-drug interaction with risperidone in rats using conditioned avoidance response (CAR) and pharmacokinetic assessments.Results: ITI-214 inhibited PDE1A (Ki = 33 pmol) with >1000-fold selectivity for the nearest other PDE family (PDE4D) and displayed minimal off-target binding interactions in a 70-substrate selectivity profile. By using specific timing of oral ITI-214 administration, it was demonstrated in the NOR that ITI-214 is able to enhance acquisition, consolidation, and retrieval memory processes. All memory effects were in the absence of effects on exploratory behavior. ITI-214 did not disrupt the risperidone pharmacokinetic profile or effects in CAR.Conclusions: ITI-214 improved the memory processes of acquisition, consolidation, and retrieval across a broad dose range (0.1–10 mg/kg, po) without disrupting the antipsychotic-like activity of a clinical antipsychotic medication, specifically risperidone. Clinical development of ITI-214 is currently in progress.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Farmaceutiska vetenskaper (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Pharmaceutical Sciences (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Farmakologi och toxikologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Pharmacology and Toxicology (hsv//eng)

Keyword

Conditioned avoidance response
Cyclic AMP
Cyclic GMP
Memory
Novel object recognition
Phosphodiesterase-1
Pharmacology
Farmakologi

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view